Diagnostic Testing for Bullous Skin Disease
Direct immunofluorescence (DIF) microscopy of perilesional skin is the essential and most critical diagnostic test for bullous pemphigoid and must be performed in all suspected cases, as its positivity is required for diagnosis. 1
Core Diagnostic Algorithm
The diagnosis requires a three-pronged approach combining clinical assessment, histopathology, and immunological testing:
1. Histopathology (Light Microscopy)
- Specimen collection: Biopsy from an early, intact bulla arising on erythematous skin
- Fixation: Place in formalin solution
- Expected findings:
- Subepidermal bullae containing eosinophils and/or neutrophils
- Dermal infiltrate of eosinophils and/or neutrophils
- Marginalization of eosinophils along the dermoepidermal junction 1
Important caveat: In nonbullous or atypical presentations, histopathology may show only nonspecific findings like eosinophilic spongiosis, making DIF even more critical 1
2. Direct Immunofluorescence (DIF) - THE GOLD STANDARD
- Specimen collection: Perilesional skin (NOT blistered skin itself)
- Transportation: Place in cryotube with liquid nitrogen, Michel's fixative, or 0.9% NaCl solution
- Expected findings: Linear (n-serrated) deposits of IgG and/or C3 along the dermoepidermal junction
- Additional patterns: Sometimes IgA and IgE with similar pattern 1
This test is non-negotiable - DIF positivity is essential for BP diagnosis and cannot be bypassed 1
3. Serological Testing (Choose ONE approach)
After confirming diagnosis with DIF, characterize circulating autoantibodies using either:
Option A: Indirect Immunofluorescence (IIF)
- Substrate: 1 mol L⁻¹ NaCl-separated normal human skin (salt-split skin)
- Expected findings: IgG antibasement membrane antibodies binding to the epidermal side of the split (sometimes both epidermal and dermal)
- Detection rate: Up to 80% of cases 1
Option B: ELISA Testing (Preferred when available)
- First-line: Anti-BP180/BPAG2 IgG antibodies
- If negative: Anti-BP230/BPAG1 IgG antibodies
- Advantage: Correlates with disease activity and guides treatment decisions 1
Clinical decision point: The choice between IIF and ELISA depends on local availability, cost, and laboratory expertise 1
Diagnostic Shortcut for Classic Presentations
When three of four clinical criteria are present, diagnosis can be made with high specificity and sensitivity if DIF shows linear IgG/C3 deposits 1:
- Age > 70 years
- Absence of atrophic scars
- Absence of mucosal involvement
- Absence of predominant bullous lesions on neck and head
Advanced/Specialized Tests (When Needed)
Use these only for difficult cases or to differentiate from other bullous diseases:
- Immunoblotting: Search for reactivity with BP180 and/or BP230
- Biochip technology: IIF with purified BP180 recombinant protein
- Fluorescence overlay antigen mapping: Assess relative location of IgG deposits
- Immunohistochemistry: Detect C3d and C4d deposits (useful when second biopsy unavailable) 1
Critical Pitfalls to Avoid
- Never biopsy blistered skin for DIF - always use perilesional skin 1
- Don't rely on C3 location in salt-split skin - only IgG location is reliable for differentiating BP from epidermolysis bullosa acquisita 1
- Don't skip DIF even with classic presentation - it remains mandatory 1
- Don't use monkey esophagus or nonseparated skin for IIF - salt-split human skin is superior 1
Practical Workflow
Obtain two biopsies simultaneously:
- One from intact bulla → formalin → histopathology
- One from perilesional skin → Michel's fixative/cryotube → DIF
Draw blood for serological testing (IIF or ELISA)
Confirm diagnosis when DIF shows linear IgG/C3 deposits + compatible histology
Characterize disease with serological tests to guide treatment intensity
This algorithmic approach ensures accurate diagnosis while avoiding unnecessary testing in straightforward cases and providing clear pathways for atypical presentations.